NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Forecast, Price & News $1.52 -0.05 (-3.18%) (As of 04:25 PM ET) Add Compare Share Share Today's Range$1.50▼$1.6450-Day Range$1.41▼$2.3152-Week Range$1.25▼$5.64Volume773,813 shsAverage Volume1.43 million shsMarket Capitalization$153.67 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Atara Biotherapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,733.1% Upside$28.00 Price TargetShort InterestBearish11.54% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.45Based on 7 Articles This WeekInsider TradingSelling Shares$102,303 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.60) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector229th out of 963 stocksBiological Products, Except Diagnostic Industry30th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Atara Biotherapeutics has a forecasted upside of 1,733.1% from its current price of $1.53.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.54% of the outstanding shares of Atara Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Atara Biotherapeutics has recently increased by 1.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atara Biotherapeutics is -0.87. Previous Next 1.9 News and Social Media Coverage News SentimentAtara Biotherapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Atara Biotherapeutics this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $102,303.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Atara Biotherapeutics is held by insiders.Percentage Held by Institutions88.79% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($2.60) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtara Biotherapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Atara Biotherapeutics (NASDAQ:ATRA) StockAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Read More ATRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRA Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Atara Biotherapeutics (NASDAQ:ATRA)September 26, 2023 | msn.comHC Wainwright & Co. Reiterates Atara Biotherapeutics (ATRA) Buy RecommendationSeptember 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 21, 2023 | finance.yahoo.comAtara (ATRA) Up 11% on Regulatory Update From Blood Cancer StudySeptember 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aptose Biosciences (APTO), Harmony Biosciences Holdings (HRMY) and Atara Biotherapeutics (ATRA)September 20, 2023 | msn.comAtara Biotherapeutics, Butterfly Network among healthcare moversSeptember 19, 2023 | msn.comAtara sees filing for FDA approval of Tab-cel in Q2 2024September 19, 2023 | finance.yahoo.comAtara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on ComparabilitySeptember 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 1, 2023 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 31, 2023 | finance.yahoo.comAtara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma ConferenceAugust 21, 2023 | msn.comAtara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis ReadoutAugust 13, 2023 | finance.yahoo.com10 Most Promising Penny Stocks According to AnalystsAugust 9, 2023 | msn.comEF Hutton Reiterates Atara Biotherapeutics (ATRA) Buy RecommendationAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Atara Biotherapeutics (ATRA)August 8, 2023 | finance.yahoo.comAtara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue EstimatesAugust 8, 2023 | finance.yahoo.comAtara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational ProgressAugust 8, 2023 | benzinga.comAtara Biotherapeutics's Earnings OutlookAugust 1, 2023 | finance.yahoo.comAtara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023July 31, 2023 | finance.yahoo.comAtara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceJune 16, 2023 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) OutlookJune 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Akebia Therapeutics (AKBA)June 7, 2023 | finance.yahoo.comAtara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 5, 2023 | finance.yahoo.comAtara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023May 30, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)May 18, 2023 | finance.yahoo.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To BeMay 17, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Atara Biotherapeutics (ATRA)See More Headlines Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATRA CUSIPN/A CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees317Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$31.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+1,730.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-228,300,000.00 Net Margins-4,437.45% Pretax Margin-4,436.94% Return on Equity-315.45% Return on Assets-94.19% Debt Debt-to-Equity RatioN/A Current Ratio2.31 Quick Ratio2.21 Sales & Book Value Annual Sales$63.57 million Price / Sales2.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.15Miscellaneous Outstanding Shares101,100,000Free Float96,552,000Market Cap$154.68 million OptionableOptionable Beta1.03 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Pascal Touchon D.V.M. (Age 60)Pres, CEO & Director Comp: $1.08MMr. K. Amar Murugan (Age 47)Exec. VP & Chief Legal Officer Comp: $618.52kDr. Jakob Dupont M.D. (Age 58)Consultant Comp: $750.53kMr. Eric Hyllengren (Age 48)Sr. VP & CFO Dr. Anhco Nguyen Ph.D. (Age 50)Exec. VP and Chief Scientific & Technical Officer Kerry Beth DalyHead of Corp. CommunicationsMr. Joseph Newell (Age 53)Exec. VP Dr. Manher Joshi M.D.Exec. VP & Chief Medical OfficerMs. Jill Henrich (Age 60)Exec. VP and Global Head of Regulatory Affairs & Quality Mr. Dan MaziaszExec. VP & Chief Bus. OfficerMore ExecutivesKey CompetitorsPardes BiosciencesNASDAQ:PRDSParatek PharmaceuticalsNASDAQ:PRTKAlpha Tau MedicalNASDAQ:DRTSKodiak SciencesNASDAQ:KODCara TherapeuticsNASDAQ:CARAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 365,210 shares on 9/21/2023Ownership: 0.035%California State Teachers Retirement SystemSold 73,988 shares on 8/21/2023Ownership: 0.031%Pascal TouchonSold 30,766 sharesTotal: $50,763.90 ($1.65/share)Amar MuruganSold 8,672 sharesTotal: $14,308.80 ($1.65/share)Eric J HyllengrenSold 8,186 sharesTotal: $13,506.90 ($1.65/share)View All Insider TransactionsView All Institutional Transactions ATRA Stock - Frequently Asked Questions Should I buy or sell Atara Biotherapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRA shares. View ATRA analyst ratings or view top-rated stocks. What is Atara Biotherapeutics' stock price forecast for 2023? 3 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their ATRA share price forecasts range from $25.00 to $31.00. On average, they expect the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 1,730.1% from the stock's current price. View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts. How have ATRA shares performed in 2023? Atara Biotherapeutics' stock was trading at $3.28 on January 1st, 2023. Since then, ATRA shares have decreased by 53.4% and is now trading at $1.53. View the best growth stocks for 2023 here. When is Atara Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ATRA earnings forecast. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.03. The biotechnology company had revenue of $0.96 million for the quarter, compared to analyst estimates of $3.36 million. Atara Biotherapeutics had a negative net margin of 4,437.45% and a negative trailing twelve-month return on equity of 315.45%. What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO? 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE). What is Atara Biotherapeutics' stock symbol? Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA." Who are Atara Biotherapeutics' major shareholders? Atara Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baupost Group LLC MA (9.67%), Wasatch Advisors LP (8.46%), BlackRock Inc. (8.17%), JPMorgan Chase & Co. (7.64%), Goldman Sachs Group Inc. (4.51%) and State Street Corp (2.51%). Insiders that own company stock include Amar Murugan, Eric J Hyllengren, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar. View institutional ownership trends. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Atara Biotherapeutics' stock price today? One share of ATRA stock can currently be purchased for approximately $1.53. How much money does Atara Biotherapeutics make? Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $154.68 million and generates $63.57 million in revenue each year. The biotechnology company earns $-228,300,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. How many employees does Atara Biotherapeutics have? The company employs 317 workers across the globe. How can I contact Atara Biotherapeutics? Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (805) 623-4211 or via email at ehyllengren@atarabio.com. This page (NASDAQ:ATRA) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.